Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Manitoba Starch Products has developed and commercialized Solnul®, a resistant potato starch with clinically demonstrated prebiotic effects. Health Canada has approved its claim to stimulate the growth of healthy bacteria in the intestine/gut based on clinical trial data showing a prebiotic effect at a 3.5g dose[6]. The product can now be marketed with this claim in Canada and potentially other regions with similar regulatory frameworks.
The company focuses on manufacturing non-GMO potato-based starches and proteins for use as functional ingredients in food products targeting human health, animal nutrition, and plant-based foods[1][2].
No pharmaceutical or drug development pipeline exists; their focus remains on food/nutraceutical applications.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Manitoba Starch Products.